Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

June 26, 2023

Study Completion Date

June 26, 2023

Conditions
Wilson Disease
Interventions
DRUG

ALXN1840

Administered as an oral tablet.

DRUG

Standard of Care

Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.

Trial Locations (20)

4101

Research Site, South Brisbane

8950

Research Site, Esplugues de Llobregat

28041

Research Site, Madrid

29011

Research Site, Málaga

30625

Research Site, Hanover

31008

Research Site, Pamplona

31059

Research Site, Toulouse

35016

Research Site, Las Palmas de Gran Canaria

59037

Research Site, Lille

72076

Research Site, Tübingen

VIC 3052

Research Site, Parkville

860-8556

Research Site, Kumamoto

830-0011

Research Site, Kurume-shi

153-8515

Research Site, Meguro-ku

063-0005

Research Site, Sapporo

04-730

Research Site, Warsaw

03080

Research Site, Seoul

03722

Research Site, Seoul

06351

Research Site, Seoul

08035

Research Site, Barcelona

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY